Does diabetes mellitus target motor neurons?

A pattern of peripheral neurodegeneration occurs in chronic diabetes mellitus in which an early, but selective retraction of distal axons may occur prior to any irretrievable neuronal loss. Clinical observations suggest that sensory systems undergo damage before those of motor neurons. In this work, we examined the fate of the spinal motor neuron in a long-term chronic model of experimental (streptozotocin-induced) diabetes already known to be associated with substantial loss of sensory neurons. The integrity, physiological function, and critical forms of protein expression of the full motor neuron tree was examined in mice exposed to 8 months of diabetes. Motor neurons developed progressive features of distal loss of axonal terminals but without perikaryal dropout, indicating distal axon retraction. While numbers and caliber of motor neuron perikarya and their nerve trunk axons were preserved, axons developed conduction velocity slowing, loss of motor units and neuromuscular junctions, and compensatory single motor unit action potential enlargement. Four critical proteins directly linked to diabetic complications were altered in motor neurons of diabetic mice: an elevated perikaryal expression of RAGE and PARP, molecules associated with cellular stress, along with concurrent rises in HSP-27 and pAKT, molecules alternatively identified with neuroprotective survival. Moreover, Akt mRNA was increased in diabetic lumbar spinal cords. Overall these findings indicate that although motor neurons are resistant to irretrievable dropout, they are targeted nonetheless by diabetes and gradually withdraw their terminals from distal innervation.

[1]  D. Zochodne,et al.  The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. , 2000, Brain : a journal of neurology.

[2]  A. Schmidt,et al.  Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes , 2002, Ageing Research Reviews.

[3]  S. Yagihashi,et al.  Pathogenetic mechanisms of diabetic neuropathy: lessons from animal models. , 1997, Journal of the peripheral nervous system : JPNS.

[4]  D. Wolgemuth,et al.  Crosstalk between p38, Hsp25 and Akt in spinal motor neurons after sciatic nerve injury. , 2001, Brain research. Molecular brain research.

[5]  M. Fahim,et al.  Muscle contractility decrement and correlated morphology during the pathogenesis of streptozotocin‐diabetic mice , 1998, The Anatomical record.

[6]  S. Kuwabara,et al.  The acute effects of glycemic control on nerve conduction in human diabetics , 2005, Clinical Neurophysiology.

[7]  H. Kiyama,et al.  Akt/Protein Kinase B Prevents Injury-Induced Motoneuron Death and Accelerates Axonal Regeneration , 2000, The Journal of Neuroscience.

[8]  G. Grimby,et al.  Muscle adaptive changes in post-polio subjects. , 1989, Scandinavian journal of rehabilitation medicine.

[9]  Sicco A Bus,et al.  Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot: a magnetic resonance imaging study. , 2002, Diabetes care.

[10]  N. Cashman,et al.  Electrophysiology and electrodiagnosis of the post-polio motor unit. , 1991, Orthopedics.

[11]  H. Vlassara,et al.  Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.

[12]  H. Andersen,et al.  Motor function in diabetic neuropathy , 1999, Acta neurologica Scandinavica.

[13]  B. Arvidson Distribution of protein tracers in peripheral ganglia : a light and electron microscopic study in rodents after various modes of tracer administration , 1979 .

[14]  D. Zochodne,et al.  Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? , 2005, Diabetes.

[15]  Jeremy M. Shefner,et al.  Motor unit number estimation in human neurological diseases and animal models , 2001, Clinical Neurophysiology.

[16]  J. Ulbrecht,et al.  Glucose-induced Alterations in Nerve Metabolism: Current Perspective on the Pathogenesis of Diabetic Neuropathy and Future Directions for Research and Therapy , 1985, Diabetes Care.

[17]  Henning Andersen,et al.  Atrophy of foot muscles: a measure of diabetic neuropathy. , 2004, Diabetes care.

[18]  S. Snyder,et al.  Poly(ADP-ribose) Polymerase-1 in the Nervous System , 2000, Neurobiology of Disease.

[19]  Johannes Buchner,et al.  Regulation of Hsp27 Oligomerization, Chaperone Function, and Protective Activity against Oxidative Stress/Tumor Necrosis Factor α by Phosphorylation* , 1999, The Journal of Biological Chemistry.

[20]  C. Helke,et al.  Abnormal PI3 kinase/Akt signal pathway in vagal afferent neurons and vagus nerve of streptozotocin-diabetic rats. , 2003, Brain research. Molecular brain research.

[21]  A. Schmidt,et al.  Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. , 2002, Advanced drug delivery reviews.

[22]  M. Gaestel,et al.  Small heat shock proteins are molecular chaperones. , 1993, The Journal of biological chemistry.

[23]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[24]  A. Goldberg,et al.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Messi,et al.  Target-Derived Trophic Effect on Skeletal Muscle Innervation in Senescent Mice , 2003, The Journal of Neuroscience.

[26]  P. Low,et al.  Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. , 1984, Brain : a journal of neurology.

[27]  D. Zochodne,et al.  Sensory neurons with activated caspase-3 survive long-term experimental diabetes. , 2003, Diabetes.

[28]  M. Matsumoto,et al.  Rage: A Novel Cellular Receptor for Advanced Glycation End Products , 1996, Diabetes.

[29]  Hideyuki Sasaki,et al.  Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats , 1997, Acta Neuropathologica.

[30]  Circulating IGF‐I and its protective role in the pathogenesis of diabetic angiopathy , 2000, Clinical endocrinology.

[31]  H. Vlassara The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.

[32]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[33]  D. Zochodne,et al.  The Influence of Indomethacin and Guanethidine on Experimental Streptozotocin Diabetic Neuropathy , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  Guido Kroemer,et al.  Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.

[35]  H. S. Neto,et al.  Acetylcholine receptors and nerve terminal distribution at the neuromuscular junction of non‐obese diabetic mice , 2002, The Anatomical record.

[36]  M. Hasan,et al.  Early morphological remodeling of neuromuscular junction in a murine model of diabetes. , 2000, Journal of applied physiology.

[37]  D. Cimino,et al.  Heat shock protein 27 stimulates recovery of RNA and protein synthesis following a heat shock , 1997, Journal of cellular biochemistry.

[38]  Fei Li,et al.  Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. , 2004, Diabetes.

[39]  E. Feldman,et al.  IGF-I prevents glutamate-induced motor neuron programmed cell death , 2004, Neurobiology of Disease.

[40]  J. Lord,et al.  Serine/threonine protein kinases and apoptosis. , 2000, Experimental cell research.

[41]  Tessa Gordon,et al.  Experimental strategies to promote functional recovery after peripheral nerve injuries , 2003, Journal of the peripheral nervous system : JPNS.

[42]  S. Hansen,et al.  Axonal dysfunction in the neuropathy of diabetes mellitus: a quantitative electrophysiological study. , 1977, Journal of neurology, neurosurgery, and psychiatry.

[43]  A. Boulton,et al.  Diabetic neuropathies and pain. , 1986, Clinics in endocrinology and metabolism.

[44]  A. Sima,et al.  New insights into the metabolic and molecular basis for diabetic neuropathy , 2003, Cellular and Molecular Life Sciences CMLS.

[45]  R. Coggeshall,et al.  Methods for determining numbers of cells and synapses: A case for more uniform standards of review , 1996, The Journal of comparative neurology.

[46]  T. Gordon,et al.  Mechanisms controlling axonal sprouting at the neuromuscular junction , 2003, Journal of neurocytology.

[47]  P. Low,et al.  Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. , 2003, Diabetes.

[48]  C. Cheng,et al.  Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. , 2001, Brain : a journal of neurology.

[49]  C. Cheng,et al.  Diabetes Mellitus and the Sensory Neuron , 2004, Journal of neuropathology and experimental neurology.

[50]  M. Cudkowicz,et al.  Comparison of incremental with multipoint MUNE methods in transgenic ALS mice , 2002, Muscle & nerve.